Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

A renowned name in rare blood disorders research, Prof. Khaled Musallam has become the first Arab to receive the Clinical ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...